中源协和涨2.02%，成交额8601.46万元，主力资金净流出334.49万元

Group 1 - The core viewpoint of the news is that Zhongyuan Qihua's stock has shown a slight increase of 2.02% recently, with a current trading price of 25.71 yuan per share and a total market capitalization of 12.031 billion yuan [1] - As of September 30, 2025, Zhongyuan Qihua reported a revenue of 1.092 billion yuan, a year-on-year decrease of 9.41%, and a net profit attributable to shareholders of 108 million yuan, down 19.18% year-on-year [2] - The company's main business revenue composition includes 58.46% from testing reagents, 26.49% from cell detection preparation and storage, 11.86% from research reagents, 2.40% from genetic testing, and 0.79% from other sources [1] Group 2 - Zhongyuan Qihua operates in the medical biology sector, specifically in medical devices and in vitro diagnostics, with concepts including stem cells, assisted reproduction, biomedicine, cancer treatment, and innovative drugs [2] - The number of shareholders for Zhongyuan Qihua increased by 4.06% to 34,700 as of September 30, 2025, while the average circulating shares per person decreased by 3.91% to 13,482 shares [2] - The company has not distributed any dividends in the last three years, with a total payout of 37.5405 million yuan since its A-share listing [3]